Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 8/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.60 |
| ▸ | BTK | Q06187 | 10/20 | 0.60 |
| ▸ | CDC7 | O00311 | 1/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | ROS1 | P08922 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | FER | P16591 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16654522 | 0.91 | JAK2 (0.62) | ATRPIK3CDBTKCDC7PLK4 | |
| SCHEMBL20533431 | 0.81 | SRC (0.63) | ATRPIK3CDBTKCDC7PLK4 | |
| SCHEMBL16655968 | 0.81 | ATR (0.74) | ATRPIK3CDBTK | |
| SCHEMBL16655945 | 0.81 | PIK3CD (0.61) | ATRPIK3CDBTKCDC7PLK4 | |
| SCHEMBL24096480 | 0.80 | JAK2 (0.86) | PIK3CDBTKCDC7PLK4DYRK3 | |
| SCHEMBL29999054 | 0.80 | JAK2 (0.86) | PIK3CDBTKCDC7PLK4DYRK3 | |
| SCHEMBL16655772 | 0.80 | ATR (0.59) | ATRPIK3CDBTKRET | |
| SCHEMBL16655615 | 0.80 | ATR (0.76) | ATRPIK3CDBTKSRCKDR | |
| SCHEMBL16655488 | 0.80 | ATR (0.59) | ATRPIK3CDBTK | |
| SCHEMBL16655347 | 0.80 | ATR (0.76) | ATRPIK3CDBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | ATR 680/4885PIK3CD 2/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.